The authorisation is expected to address the material shortages and enable laboratories to accelerate testing regardless of instrument or reagent availability.Īlso, the clinical laboratories will be able to process few thousands of samples per day, at a price of less than $10 per sample running the assay on a single MassARRAY instrument, said the company.Īgena Bioscience claimed that its new MassARRAY SARS-CoV-2 Panel is one of the few highest throughput SARS-CoV-2 tests, to receive FDA EUA. MassARRAY SARS-CoV-2 Panel is a high throughput Covid-19 test Most real time qPCR-based assays target only two or three targets on the viral genome.” The MassARRAY System is the perfect tool for that.”Īgena Bioscience scientific affairs vice president Darryl Irwin said: “The MassARRAY SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome. To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. MassARRAY instrument is used in fields including cancer profiling, solid tumours and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research, said the company.Īgena Bioscience CEO Peter Dansky said: “Agena is proud to offer a truly scalable platform to support the increasing demand for high-throughput SARS-CoV-2 testing. The assay runs on a single MassARRAY instrument, a high-sensitive mass spectrometry-based platform used for high-throughput genetic analysis.
The single-reaction panel is designed to target five regions of the viral genome and delivers enhanced accuracy and sensitivity.
Agena Bioscience has secured the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its MassARRAY SARS-CoV-2 Panel to detect coronavirus.
0 kommentar(er)
